Barclays PLC lifted its position in Generation Bio Co. (NASDAQ:GBIO – Free Report) by 165.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 76,430 shares of the company’s stock after purchasing an additional 47,639 shares during the period. Barclays PLC owned about 0.11% of Generation Bio worth $189,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently added to or reduced their stakes in the company. Rhumbline Advisers increased its holdings in Generation Bio by 7.4% in the second quarter. Rhumbline Advisers now owns 78,903 shares of the company’s stock valued at $222,000 after buying an additional 5,430 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Generation Bio by 2.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 423,299 shares of the company’s stock valued at $1,046,000 after purchasing an additional 8,692 shares in the last quarter. Cubist Systematic Strategies LLC raised its holdings in Generation Bio by 91.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 19,046 shares of the company’s stock worth $54,000 after purchasing an additional 9,075 shares during the period. State Street Corp boosted its position in Generation Bio by 1.2% during the third quarter. State Street Corp now owns 992,188 shares of the company’s stock worth $2,451,000 after purchasing an additional 11,669 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in Generation Bio by 8.7% in the second quarter. The Manufacturers Life Insurance Company now owns 164,573 shares of the company’s stock valued at $464,000 after purchasing an additional 13,104 shares during the period. 95.22% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
GBIO has been the subject of several research analyst reports. Needham & Company LLC reduced their target price on Generation Bio from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Wedbush restated an “outperform” rating and set a $5.00 price objective on shares of Generation Bio in a research report on Thursday, November 7th.
Generation Bio Trading Up 4.4 %
GBIO stock opened at $0.99 on Wednesday. Generation Bio Co. has a 12-month low of $0.75 and a 12-month high of $4.65. The business’s 50-day moving average is $1.20 and its 200 day moving average is $2.07. The stock has a market cap of $66.12 million, a price-to-earnings ratio of -0.45 and a beta of 2.72.
Insider Transactions at Generation Bio
In other Generation Bio news, Director Anthony G. Quinn bought 85,000 shares of Generation Bio stock in a transaction dated Monday, January 13th. The stock was acquired at an average cost of $0.97 per share, for a total transaction of $82,450.00. Following the completion of the transaction, the director now directly owns 299,286 shares of the company’s stock, valued at approximately $290,307.42. This represents a 39.67 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 21.10% of the company’s stock.
Generation Bio Company Profile
Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.
Featured Articles
- Five stocks we like better than Generation Bio
- What is the S&P 500 and How It is Distinct from Other Indexes
- SAP’s Strong Momentum: A Bullish Setup for Investors
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- How to Calculate Stock Profit
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
Want to see what other hedge funds are holding GBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Generation Bio Co. (NASDAQ:GBIO – Free Report).
Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.